Data from experiments clearly indicated that silibinin could suppress tumorsphere formation and its specific CSC marker genes (SOX2, OCT4, and NANOG), suggesting the ability of silibinin to suppress mutation in CSC signaling and for use in chemotherapy, as it can target CSC to prevent cancer recurrence. Here, NANOG is linked to cancer.